Bank Of America Corp Lian Bio Transaction History

Bank Of America Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.33 - $4.6 $3,210 - $11,104	2,414 Added 21.93%	13,424 $60,000
Q2 2023 Aug 14, 2023	SELL	$1.79 - $2.85 $3,173 - $5,053	-1,773 Reduced 13.87%	11,010 $25,000
Q1 2023 May 12, 2023	BUY	$1.57 - $2.66 $394 - $667	251 Added 2.0%	12,783 $25,000
Q4 2022 Feb 10, 2023	BUY	$1.14 - $2.11 $4,964 - $9,189	4,355 Added 53.26%	12,532 $20,000
Q3 2022 Nov 14, 2022	BUY	$1.87 - $3.0 $13,415 - $21,522	7,174 Added 715.25%	8,177 $16,000
Q2 2022 Aug 12, 2022	BUY	$2.15 - $6.01 $1,997 - $5,583	929 Added 1255.41%	1,003 $2,000
Q1 2022 May 16, 2022	SELL	$2.8 - $6.21 $235,989 - $523,391	-84,282 Reduced 99.91%	74 $0
Q4 2021 Feb 08, 2022	BUY	$6.14 - $16.2 $517,945 - $1.37 Million	84,356 New	84,356 $519,000

1.1M

Ticker LIAN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,354,000
Market Cap $32.5M
Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with p...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.